Mehmet Muhittin Yalcin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mehmet Muhittin Yalcin has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Alev Eroglu Altinova
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye
19 shared publications - Mujde Akturk
Gazi University
18 shared publications - Fusun Balos Toruner
Gazi University
17 shared publications - Ayhan Karakoc
Department of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Türkiye
13 shared publications - Meric Coskun
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye
11 shared publications - Tugba Barlas
Faculty of Medicine, Department of Endocrinology and Metabolism, Gazi University, Ankara, Turkey
11 shared publications
Latest Publications
- 28 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (11) , 5736-5751
Long-Term Outcomes and Predictors of Recurrent Weight Gain After Sleeve Gastrectomy, Roux-En-Y Gastric Bypass, and One Anastomosis Gastric Bypass: Turkish Metabolic and Bariatric Surgery Follow-up Study (TMBS Study)
- 28 September 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (11) , 5736-5751
Long-Term Outcomes and Predictors of Recurrent Weight Gain After Sleeve Gastrectomy, Roux-En-Y Gastric Bypass, and One Anastomosis Gastric Bypass: Turkish Metabolic and Bariatric Surgery Follow-up Study (TMBS Study)
- Open Access
- 1 September 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
The Evaluation of the Predictive Value of Early Postoperative Biochemical Parameters for Remission in Patients with Acromegaly
Objective: This study aimed to evaluate the predictive value of growth hormone (GH), insulin-like growth factor-1 (IGF-1), calcium (Ca), and phosphorus (P) levels in the first 2-4 days after surgery for achieving biochemical remission in patients with newly diagnosed acromegaly. Methods: This retrospective cohort study included patients with acromegaly who underwent surgery. Preoperative and early postoperative days 2-4 (POD2-4), 3rd month, and 12th month serum levels of GH, IGF-1, Ca, and P were obtained. Age-normalized IGF-1 levels defined remission at 3-6 months, and patients were grouped accordingly. Results: Biochemical remission was achieved in 44 of 68 patients (64.7%). Preoperative GH, IGF-1, and Ca were significantly higher in the non-remission group (all P < .05), while P did not differ. In POD2-4, all parameters, including P, were significantly higher in the non-remission group (P < .05). Receiver operating characteristic (ROC) analysis showed that a GH ≤1.28 in POD2-4 (AUC = 0.858, sensitivity: 0.74, specificity: 0.88) and a ≥45.29% decrease in IGF-1 from preoperative values (AUC = 0.816; sensitivity: 0.73, specificity: 0.79) predicted remission. At 12 months, GH and IGF-1 remained significantly different, whereas Ca and P did not (P = .67 and P = .20). Conclusion: In patients with acromegaly, GH, IGF-1, Ca, and P levels measured in the first 2-4 days after surgery were found to be significantly lower in the remission group than in those who did not achieve remission. Postoperative GH levels and the percentage decrease in IGF-1 levels were associated with remission and may help with early risk stratification. Cite this article as: Babayeva A, Coskun M, Ozturk O, et al. The evaluation of the predictive value of early postoperative biochemical parameters for remission in patients with acromegaly. Endocrinol Res Pract. Published online September 1, 2026. doi: 10.5152/erp.2026.26985
- 1 September 2026
- Published by AVES YAYINCILIK A.Ş. in Endocrinology Research and Practice
Open AccessThe Evaluation of the Predictive Value of Early Postoperative Biochemical Parameters for Remission in Patients with Acromegaly
Objective: This study aimed to evaluate the predictive value of growth hormone (GH), insulin-like growth factor-1 (IGF-1), calcium (Ca), and phosphorus (P) levels in the first 2-4 days after surgery for achieving biochemical remission in patients with newly diagnosed acromegaly. Methods: This retrospective cohort study included patients with acromegaly who underwent surgery. Preoperative and early postoperative days 2-4 (POD2-4), 3rd month, and 12th month serum levels of GH, IGF-1, Ca, and P were obtained. Age-normalized IGF-1 levels defined remission at 3-6 months, and patients were grouped accordingly. Results: Biochemical remission was achieved in 44 of 68 patients (64.7%). Preoperative GH, IGF-1, and Ca were significantly higher in the non-remission group (all P < .05), while P did not differ. In POD2-4, all parameters, including P, were significantly higher in the non-remission group (P < .05). Receiver operating characteristic (ROC) analysis showed that a GH ≤1.28 in POD2-4 (AUC = 0.858, sensitivity: 0.74, specificity: 0.88) and a ≥45.29% decrease in IGF-1 from preoperative values (AUC = 0.816; sensitivity: 0.73, specificity: 0.79) predicted remission. At 12 months, GH and IGF-1 remained significantly different, whereas Ca and P did not (P = .67 and P = .20). Conclusion: In patients with acromegaly, GH, IGF-1, Ca, and P levels measured in the first 2-4 days after surgery were found to be significantly lower in the remission group than in those who did not achieve remission. Postoperative GH levels and the percentage decrease in IGF-1 levels were associated with remission and may help with early risk stratification. Cite this article as: Babayeva A, Coskun M, Ozturk O, et al. The evaluation of the predictive value of early postoperative biochemical parameters for remission in patients with acromegaly. Endocrinol Res Pract. Published online September 1, 2026. doi: 10.5152/erp.2026.26985
- Open Access
- 24 February 2026
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 21 (1) , 41
Clinical features of osteoporosis in patients with type 1 and type 2 diabetes in Türkiye: A nationwide study
Summary: This nationwide study assessed clinical features of osteoporosis in Turkish adults with diabetes. Osteoporosis prevalence was 9.36% in type 1 diabetes and 19.13% in type 2 diabetes, with higher rates in women and older individuals. Although overall fracture prevalence was low, fractures were markedly more frequent in patients with osteoporosis. Despite the high burden, most patients did not receive osteoporosis therapy, and age, female sex, and vascular complications were independently associated with osteoporosis. Aim: Fragility fractures related to diabetes are increasing worldwide with rising life expectancy. We aimed to investigate the prevalence of osteoporosis and its associated factors in a large nationwide cohort of adults with type 1 (T1DM) and type 2 diabetes (T2DM) in Türkiye. Methods: Using Turkish Ministry of Health electronic health records (2015–2021), adults with T1DM and T2DM were identified and classified according to the presence or absence of osteoporosis. Demographics, comorbidities, diabetes-related complications, fracture diagnoses, and laboratory parameters were analyzed. Factors independently associated with osteoporosis were evaluated using multivariable logistic regression. Results: The cohort included 76,742 individuals with T1DM (mean age 44.3 ± 19.1 years; 45.8% women) and 7,006,910 with T2DM (mean age 59.1 ± 13.4 years; 60.2% women). Overall osteoporosis prevalence was 19.03% and was 9.3% in T1DM and 19.1% in T2DM. Osteoporosis was more frequent in women than men (T1DM: 14.17% vs 5.29% p < 0.001; T2DM: 27.76% vs 6.04% p < 0.001) and increased with age in both diabetes types. Fractures occurred in 0.22% of patients with T1DM and 0.21% of those with T2DM. In T1DM, fracture frequency was approximately sixfold higher in patients with osteoporosis than in those without osteoporosis (RR ≈ 6.92; 95% CI 5.09–9.39; p < 0.001), whereas in T2DM osteoporosis was associated with an approximately fourfold higher fracture frequency (RR ≈ 3.98). Macrovascular and microvascular complications were more frequent among osteoporosis patients with T1DM than those with T2DM. Only 13.4% of patients with osteoporosis received pharmacological osteoporosis therapy. In multivariable analysis, older age (OR 1.06), female sex (OR 6.58), cardiovascular disease (OR 1.58), and microvascular complications (OR 1.38) were independently associated with osteoporosis. Conclusion: In this nationwide Turkish cohort, osteoporosis affected 9.36% of adults with T1DM and 19.13% of those with T2DM. Among patients with osteoporosis, vascular complications were more prevalent in T1DM than in T2DM.Despite the substantial disease burden and the markedly higher fracture frequency in individuals with osteoporosis, most patients remained untreated.
- 24 February 2026
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 21 (1) , 41
Open AccessClinical features of osteoporosis in patients with type 1 and type 2 diabetes in Türkiye: A nationwide study
Summary: This nationwide study assessed clinical features of osteoporosis in Turkish adults with diabetes. Osteoporosis prevalence was 9.36% in type 1 diabetes and 19.13% in type 2 diabetes, with higher rates in women and older individuals. Although overall fracture prevalence was low, fractures were markedly more frequent in patients with osteoporosis. Despite the high burden, most patients did not receive osteoporosis therapy, and age, female sex, and vascular complications were independently associated with osteoporosis. Aim: Fragility fractures related to diabetes are increasing worldwide with rising life expectancy. We aimed to investigate the prevalence of osteoporosis and its associated factors in a large nationwide cohort of adults with type 1 (T1DM) and type 2 diabetes (T2DM) in Türkiye. Methods: Using Turkish Ministry of Health electronic health records (2015–2021), adults with T1DM and T2DM were identified and classified according to the presence or absence of osteoporosis. Demographics, comorbidities, diabetes-related complications, fracture diagnoses, and laboratory parameters were analyzed. Factors independently associated with osteoporosis were evaluated using multivariable logistic regression. Results: The cohort included 76,742 individuals with T1DM (mean age 44.3 ± 19.1 years; 45.8% women) and 7,006,910 with T2DM (mean age 59.1 ± 13.4 years; 60.2% women). Overall osteoporosis prevalence was 19.03% and was 9.3% in T1DM and 19.1% in T2DM. Osteoporosis was more frequent in women than men (T1DM: 14.17% vs 5.29% p < 0.001; T2DM: 27.76% vs 6.04% p < 0.001) and increased with age in both diabetes types. Fractures occurred in 0.22% of patients with T1DM and 0.21% of those with T2DM. In T1DM, fracture frequency was approximately sixfold higher in patients with osteoporosis than in those without osteoporosis (RR ≈ 6.92; 95% CI 5.09–9.39; p < 0.001), whereas in T2DM osteoporosis was associated with an approximately fourfold higher fracture frequency (RR ≈ 3.98). Macrovascular and microvascular complications were more frequent among osteoporosis patients with T1DM than those with T2DM. Only 13.4% of patients with osteoporosis received pharmacological osteoporosis therapy. In multivariable analysis, older age (OR 1.06), female sex (OR 6.58), cardiovascular disease (OR 1.58), and microvascular complications (OR 1.38) were independently associated with osteoporosis. Conclusion: In this nationwide Turkish cohort, osteoporosis affected 9.36% of adults with T1DM and 19.13% of those with T2DM. Among patients with osteoporosis, vascular complications were more prevalent in T1DM than in T2DM.Despite the substantial disease burden and the markedly higher fracture frequency in individuals with osteoporosis, most patients remained untreated.
- 1 August 2025
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 133 (08) , 408-414
Experience with the Mixed Meal Test in Diagnosing GIP-Dependent Cortisol Hypersecretion at a Tertiary Center
Aberrant expression of glucose-dependent insulinotropic peptide receptors (GIPR) might regulate increased steroidogenesis in patients with ACTH-independent cortisol hypersecretion. This study investigated the presence of aberrant GIPR expression in patients with ACTH-independent cortisol hypersecretion and bilateral adrenal adenomas.Patients with bilateral adrenal adenomas, ACTH-independent CS and aberrant GIPR screened via mixed meal test were included. Patients’ demographic features and laboratory and imaging findings were obtained retrospectively.Twenty-one patients were included. Overt CS findings were present in 14.3% of the patients. One patient (4.7%) had a complete positive response (537% increase) and one patient (4.7%) had a partial response (41% increase) to the mixed meal test. In the remaining 19 patients, a mean change of -10.1% (range: −56.5% to+24.7%) in cortisol levels was observed at 120 min compared to baseline. The patient with a complete positive response was confirmed using 100 µg of IV octreotide. The patient underwent unilateral adrenalectomy after an inadequate long-term response to octreotide LAR therapy. The histopathology revealed bilateral macronodular adrenal cortical disease. We identified a germline heterozygous frameshift variant in the KDM1A gene in the patient’s blood sample and a recurrent deletion of the p arm of chromosome 1 harboring the KDM1A locus in the adrenal sample.These results may provide useful insights into the screening of aberrant GIPR expression in patients with ACTH-independent hypercortisolism. It is essential to further investigate which patients require screening. Moreover, a significant cortisol peak observed during the mixed meal test in the presence of these receptors has drawn attention.
- 1 August 2025
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 133 (08) , 408-414
Experience with the Mixed Meal Test in Diagnosing GIP-Dependent Cortisol Hypersecretion at a Tertiary Center
Aberrant expression of glucose-dependent insulinotropic peptide receptors (GIPR) might regulate increased steroidogenesis in patients with ACTH-independent cortisol hypersecretion. This study investigated the presence of aberrant GIPR expression in patients with ACTH-independent cortisol hypersecretion and bilateral adrenal adenomas.Patients with bilateral adrenal adenomas, ACTH-independent CS and aberrant GIPR screened via mixed meal test were included. Patients’ demographic features and laboratory and imaging findings were obtained retrospectively.Twenty-one patients were included. Overt CS findings were present in 14.3% of the patients. One patient (4.7%) had a complete positive response (537% increase) and one patient (4.7%) had a partial response (41% increase) to the mixed meal test. In the remaining 19 patients, a mean change of -10.1% (range: −56.5% to+24.7%) in cortisol levels was observed at 120 min compared to baseline. The patient with a complete positive response was confirmed using 100 µg of IV octreotide. The patient underwent unilateral adrenalectomy after an inadequate long-term response to octreotide LAR therapy. The histopathology revealed bilateral macronodular adrenal cortical disease. We identified a germline heterozygous frameshift variant in the KDM1A gene in the patient’s blood sample and a recurrent deletion of the p arm of chromosome 1 harboring the KDM1A locus in the adrenal sample.These results may provide useful insights into the screening of aberrant GIPR expression in patients with ACTH-independent hypercortisolism. It is essential to further investigate which patients require screening. Moreover, a significant cortisol peak observed during the mixed meal test in the presence of these receptors has drawn attention.
- 30 April 2025
- Published by Bulent Evcevit University in Medical Journal of Western Black Sea
- Vol. 9 (1) , 83-89
Real-World Data on the Development of Relapse in Graves' Disease from a Tertiary Referral Center
Aim: We aimed to evaluate clinical and laboratory parameters that may predict relapse in patients who have received adequate antithyroid drug (ATD) therapy for Graves’ disease (GD). Material and Methods: We included patients with GD who received ATD therapy for at least 12 months and were followed for at least 12 months after treatment. Patients were classified into relapse and non-relapse groups, and their demographical, laboratory, imaging findings, and follow-up information were recorded retrospectively. Results: Eighty-three patients were included, with a median treatment duration of 18 (13-24) month. Graves' orbitopathy (GO) was present in 58 (69.9%) of patients, and 17 (20.5%) received steroid therapy for GO. Relapse occurred in 27 (32.5%) of patients, with a median time to relapse of 22 (6-60) months, and 11 (40.7%) relapsed within the first 12 months. No association was found between TRAb positivity at diagnosis and relapse (p=0.542), but higher TRAb levels at ATD discontinuation (p=0.026), larger thyroid volumes (p=0.043), and lower TSH levels at diagnosis (p=0.027) were related with increased relapse risk. In the whole patient group, GH relapse was lower in those treated with corticosteroids as GO therapy (p=0.030). The regression model identified thyroid volume (p=0.044) and corticosteroid usage for GO (p=0.042) as predictors of relapse. Conclusion: Our findings suggest that while GH relapse might be more frequent in patients with larger thyroid volumes, corticosteroid therapy administered for GO may serve as a protective factor for GH relaps. The real-world data from our tertiary referral center may contribute to studies on GD relapse development, especially when considering sociodemographical differences.
- 30 April 2025
- Published by Bulent Evcevit University in Medical Journal of Western Black Sea
- Vol. 9 (1) , 83-89
Real-World Data on the Development of Relapse in Graves' Disease from a Tertiary Referral Center
Aim: We aimed to evaluate clinical and laboratory parameters that may predict relapse in patients who have received adequate antithyroid drug (ATD) therapy for Graves’ disease (GD). Material and Methods: We included patients with GD who received ATD therapy for at least 12 months and were followed for at least 12 months after treatment. Patients were classified into relapse and non-relapse groups, and their demographical, laboratory, imaging findings, and follow-up information were recorded retrospectively. Results: Eighty-three patients were included, with a median treatment duration of 18 (13-24) month. Graves' orbitopathy (GO) was present in 58 (69.9%) of patients, and 17 (20.5%) received steroid therapy for GO. Relapse occurred in 27 (32.5%) of patients, with a median time to relapse of 22 (6-60) months, and 11 (40.7%) relapsed within the first 12 months. No association was found between TRAb positivity at diagnosis and relapse (p=0.542), but higher TRAb levels at ATD discontinuation (p=0.026), larger thyroid volumes (p=0.043), and lower TSH levels at diagnosis (p=0.027) were related with increased relapse risk. In the whole patient group, GH relapse was lower in those treated with corticosteroids as GO therapy (p=0.030). The regression model identified thyroid volume (p=0.044) and corticosteroid usage for GO (p=0.042) as predictors of relapse. Conclusion: Our findings suggest that while GH relapse might be more frequent in patients with larger thyroid volumes, corticosteroid therapy administered for GO may serve as a protective factor for GH relaps. The real-world data from our tertiary referral center may contribute to studies on GD relapse development, especially when considering sociodemographical differences.
- 17 February 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (2) , 148-159
A deep dive into four thyroglobulin immunoassays from analytical perspective
Serum thyroglobulin immunometric assays (sTg) are crucial for monitoring differentiated thyroid cancer (DTC) treatment. However, challenges such as anti-thyroglobulin autoantibodies (TgAb) and assay variability hinder evaluations. This study assessed four sTg methods-three second-generation (Architect, Access, Elecsys) and one first-generation (Immulite)-following Clinical and Laboratory Standards Institute (CLSI) and American Thyroid Association (ATA) guidelines. The study compared sTg(Architect), sTg(Access), sTg(Elecsys), and sTg(Immulite). Precision was evaluated per CLSI EP05-A3, while the lower limits of detection (LLD) were assessed using EP17-A2. Passing-Bablok and Bland-Altman analyses were conducted as per EP09c, and semi-quantitative comparisons used Kappa statistics. The second-generation sTgs (Architect, Access, Elecsys) exhibited satisfactory precision ( 0.884) across all concentration ranges (≤1, 1-10, >10 μg/L), with biases (slope: 1.131-2.027). sTg(Immulite) correlated well with second-generation methods for concentrations >10 μg/L (r > 0.945) but less so for r < 0.642). TgAb significantly impacted sTg(Immulite). Kappa statistics revealed strong agreement among second-generation methods (κ > 0.800) but lower concordance with sTg(Immulite), especially in TgAb(+) samples (κ: 0.562-0.653). Agreement ratios were high for second-generation methods (0.667-1.000) but variable for sTg(Immulite), particularly at lower concentrations and in TgAb(+) cases (0.097-0.727). sTg(Immulite) did not meet LLD and precision criteria for DTC monitoring, facing issues with TgAb interference. Second-generation sTgs demonstrated consistent performance across all concentrations.
- 17 February 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (2) , 148-159
A deep dive into four thyroglobulin immunoassays from analytical perspective
Serum thyroglobulin immunometric assays (sTg) are crucial for monitoring differentiated thyroid cancer (DTC) treatment. However, challenges such as anti-thyroglobulin autoantibodies (TgAb) and assay variability hinder evaluations. This study assessed four sTg methods-three second-generation (Architect, Access, Elecsys) and one first-generation (Immulite)-following Clinical and Laboratory Standards Institute (CLSI) and American Thyroid Association (ATA) guidelines. The study compared sTg(Architect), sTg(Access), sTg(Elecsys), and sTg(Immulite). Precision was evaluated per CLSI EP05-A3, while the lower limits of detection (LLD) were assessed using EP17-A2. Passing-Bablok and Bland-Altman analyses were conducted as per EP09c, and semi-quantitative comparisons used Kappa statistics. The second-generation sTgs (Architect, Access, Elecsys) exhibited satisfactory precision ( 0.884) across all concentration ranges (≤1, 1-10, >10 μg/L), with biases (slope: 1.131-2.027). sTg(Immulite) correlated well with second-generation methods for concentrations >10 μg/L (r > 0.945) but less so for r < 0.642). TgAb significantly impacted sTg(Immulite). Kappa statistics revealed strong agreement among second-generation methods (κ > 0.800) but lower concordance with sTg(Immulite), especially in TgAb(+) samples (κ: 0.562-0.653). Agreement ratios were high for second-generation methods (0.667-1.000) but variable for sTg(Immulite), particularly at lower concentrations and in TgAb(+) cases (0.097-0.727). sTg(Immulite) did not meet LLD and precision criteria for DTC monitoring, facing issues with TgAb interference. Second-generation sTgs demonstrated consistent performance across all concentrations.
- 27 January 2025
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 86 (2) , 101706
Co-existing autonomous cortisol secretion in primary aldosteronism
- 27 January 2025
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 86 (2) , 101706
Co-existing autonomous cortisol secretion in primary aldosteronism
- Open Access
- 21 January 2025
- Published by Springer Nature in Journal of Eating Disorders
- Vol. 13 (1) , 1-9
Assessment of diabetes-specific eating disorder risk in adult patients with diabetes
Adults with type 1 diabetes (T1D) are reported to be at higher risk for clinical eating disorders (ED) and other disordered eating behaviors (DEB) than their peers without diabetes. On the other hand, there is insufficient data on DEB in adults with type 2 diabetes (T2D). Our study aimed to investigate the prevalence of DEB in patients with T1D and T2D on intensive insulin therapy followed in our outpatient clinic. Diabetes Eating Problem Survey-Revised (DEPS-R), electronically delivered to the patients with T1D and T2D who were on an intensive insulin regimen followed up in the diabetes outpatient clinic in our center for the evaluation of DEB. A total of 120 participants, 80 patients with T1D and 40 patients with T2D, were included in the study. DEB was defined as a DEPS-R score ≥ 20 according to the answers given to the questionnaire. Risk of DEB was observed in 35% of all individuals with diabetes and was higher in T2D (55% (n = 22)) than in T1D (25% (n = 20)) (p < 0.001). In patients with T1D, BMI was similar between the risk and normal groups in terms of DEB (p = 0.15), whereas in patients with T2D, BMI was significantly higher in the risk group in terms of DEB compared to the non-risk group (p < 0.001). There was a positive correlation between the risk of DEB and HbA1c and a negative correlation with the duration of diabetes in the T1D group (p < 0.05). Weight loss was an important goal for more than 50% of individuals with diabetes in both groups, more than 60% said they skipped a main meal or snack. 13.8% of those with T1D and 27.5% of those with T2D preferred being thin to having their diabetes better controlled. In our study, 35% of patients with diabetes were found to have a risk of DEB, with the risk being higher in the T2D group. Our results emphasize the importance of increasing awareness among physicians and patients about DEB, which is prevalent among patients with diabetes. Early detection of individuals at risk for DEB should be considered a crucial aspect of treatment. Studies have reported that adults with diabetes are at a higher risk for eating disorders (ED) compared to their peers without diabetes. However, this issue has not been thoroughly explored in adults with type 2 diabetes (T2D). Therefore, our aim was to investigate the prevalence of disordered eating behaviors (DEB) in patients with type 1 diabetes (T1D) who were receiving intensive insulin therapy, as well as in patients with T2D at our outpatient clinic. The Diabetes Eating Problem Survey-Revised (DEPS-R) was electronically delivered to the participants for the evaluation of DEB. The survey results, revealed that 35% of all individuals with diabetes exhibited a risk of DEB, with a higher prevalence in those with T2D compared to those with T1D. In patients with T1D, the body mass index (BMI) was similar between risk and non-risk groups in terms of DEB. However, in patients with T2D, the BMI was significantly higher in the at-risk group than in the non-at-risk group. Additionally, over 50% of individuals with diabetes in both groups identified weight loss as an important goal, and more than 60% admitted to skipping meals or snacks. Interestingly, 13.8% of patients with T1D and 27.5% patients with T2D expressed a preference for being thin over having better of their diabetes. Our study underscores that 35% of individuals with diabetes are at risk for DEB, with a higher risk in the T2D group. These findings emphasize the necessity of increasing awareness among physicians and patients regarding the prevalence of disordered eating behavior among patients with diabetes. Early identification of individuals at risk for DEB should be considered an essential component of treatment.
- 21 January 2025
- Published by Springer Nature in Journal of Eating Disorders
- Vol. 13 (1) , 1-9
Open AccessAssessment of diabetes-specific eating disorder risk in adult patients with diabetes
Adults with type 1 diabetes (T1D) are reported to be at higher risk for clinical eating disorders (ED) and other disordered eating behaviors (DEB) than their peers without diabetes. On the other hand, there is insufficient data on DEB in adults with type 2 diabetes (T2D). Our study aimed to investigate the prevalence of DEB in patients with T1D and T2D on intensive insulin therapy followed in our outpatient clinic. Diabetes Eating Problem Survey-Revised (DEPS-R), electronically delivered to the patients with T1D and T2D who were on an intensive insulin regimen followed up in the diabetes outpatient clinic in our center for the evaluation of DEB. A total of 120 participants, 80 patients with T1D and 40 patients with T2D, were included in the study. DEB was defined as a DEPS-R score ≥ 20 according to the answers given to the questionnaire. Risk of DEB was observed in 35% of all individuals with diabetes and was higher in T2D (55% (n = 22)) than in T1D (25% (n = 20)) (p < 0.001). In patients with T1D, BMI was similar between the risk and normal groups in terms of DEB (p = 0.15), whereas in patients with T2D, BMI was significantly higher in the risk group in terms of DEB compared to the non-risk group (p < 0.001). There was a positive correlation between the risk of DEB and HbA1c and a negative correlation with the duration of diabetes in the T1D group (p < 0.05). Weight loss was an important goal for more than 50% of individuals with diabetes in both groups, more than 60% said they skipped a main meal or snack. 13.8% of those with T1D and 27.5% of those with T2D preferred being thin to having their diabetes better controlled. In our study, 35% of patients with diabetes were found to have a risk of DEB, with the risk being higher in the T2D group. Our results emphasize the importance of increasing awareness among physicians and patients about DEB, which is prevalent among patients with diabetes. Early detection of individuals at risk for DEB should be considered a crucial aspect of treatment. Studies have reported that adults with diabetes are at a higher risk for eating disorders (ED) compared to their peers without diabetes. However, this issue has not been thoroughly explored in adults with type 2 diabetes (T2D). Therefore, our aim was to investigate the prevalence of disordered eating behaviors (DEB) in patients with type 1 diabetes (T1D) who were receiving intensive insulin therapy, as well as in patients with T2D at our outpatient clinic. The Diabetes Eating Problem Survey-Revised (DEPS-R) was electronically delivered to the participants for the evaluation of DEB. The survey results, revealed that 35% of all individuals with diabetes exhibited a risk of DEB, with a higher prevalence in those with T2D compared to those with T1D. In patients with T1D, the body mass index (BMI) was similar between risk and non-risk groups in terms of DEB. However, in patients with T2D, the BMI was significantly higher in the at-risk group than in the non-at-risk group. Additionally, over 50% of individuals with diabetes in both groups identified weight loss as an important goal, and more than 60% admitted to skipping meals or snacks. Interestingly, 13.8% of patients with T1D and 27.5% patients with T2D expressed a preference for being thin over having better of their diabetes. Our study underscores that 35% of individuals with diabetes are at risk for DEB, with a higher risk in the T2D group. These findings emphasize the necessity of increasing awareness among physicians and patients regarding the prevalence of disordered eating behavior among patients with diabetes. Early identification of individuals at risk for DEB should be considered an essential component of treatment.
- 11 October 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (4) , 433-437
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients - Gazi Medical Journal
- 11 October 2024
- Published by Galenos Yayinevi in Gazi Medical Journal
- Vol. 35 (4) , 433-437
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients - Gazi Medical Journal